Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Safety data on AstraZeneca anemia drug points to potential use in dialysis

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo

FRANKFURT (Reuters) - AstraZeneca said on Friday that safety data on roxadustat underpinned the British drugmaker's hopes for the anemia drug to become a standard treatment for patients with kidney disease.

It said pooled data from several late-stage trials showed that roxadustat did not increase the risk of potentially deadly cardiovascular complications like heart attacks and strokes when used instead of epo, which is the standard treatment for dialysis patients against lack of red blood cells from kidney disease.

(Reporting by Ludwig Burger; Editing by Elaine Hardcastle)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.